TO: USPTO RECEIVED CENTRAL FAX CENTER

FEB **0 3** 2005

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Appln. Ser. No.:	Filed:	Inventor(s):	Atty Dkt:
09/891,881	06/26/2001	J. Voorhees	100UM-010A

Title: Use of EGF-R Protein Tyrosine Kinase Inhibitors

Examiner: R. Winston Art Unit: 1654

Mail Stop AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 VIA FACSIMILE 571-273-8300

P.1/9

RESPONSE and AMENDMENT

Dear Sir:

In complete response to the Office action mailed 8 June 2004, and the Notice of Non-Compliant Amendment mailed 25 January 2005, please first amend the claims as shown on the following four pages, after which are remarks.

Respectfully submitted,

Bradley N. Ruben, PC

463 First St., Suite 5A Hoboken, NJ 07030-1859

201-239-0707 (fax -0734)

mail@rubenpatent.com

3 February 2005

Bradley N. Ruben, Reg. No. 32,058

CERTIFICATE OF MAILING OR TRANSMISSION - 37 CFR 1.8

I hereby certify that I have a reasonable basis that this paper, along with any referred to above, (i) are being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, or (ii) are being transmitted to the U.S. Patent & Tredemark Office in accordance with 37 CFR § 1.6(d).

DATE 3 Februar 2005

NAME: Brad Kuben

SIGNATURE Brade

09/891,881

Page 1 of 9

100UM-010A